抗波形蛋白抗体相关早期抗体介导的肾移植排斥反应:一例病例报告
本文报告一例21岁IgA肾病肾衰竭患者,接受母亲单倍型活体肾移植,术前无致敏、抗HLA供者特异性抗体阴性且流式交叉配型阴性,符合低免疫记忆风险标准。术后第2天出现移植肾功能延迟恢复,活检提示抗体介导排斥反应和急性肾小管损伤,非HLA抗体筛查检出预存抗波形蛋白抗体。经血浆置换、静脉免疫球蛋白、抗胸腺细胞球蛋白和甲泼尼龙治疗后肾功能恢复,随访1年移植物功能稳定。
要点
- 传统低免疫风险肾移植受者仍可发生非HLA抗体相关排斥。
- 预存抗波形蛋白抗体可能与缺血再灌注损伤后暴露的抗原表位结合。
- 非HLA抗体筛查有助于个体化评估移植排斥风险。
核心结论
- 预存抗波形蛋白抗体可能参与早期抗体介导的肾移植排斥反应,其致病表位可能在缺血再灌注损伤中暴露。
研究设计与样本
- 单例病例报告:21岁男性,IgA肾病致肾衰竭,接受母亲单倍型活体肾移植。
主要发现
- 术后第2天出现移植肾功能延迟恢复,活检提示抗体介导排斥反应和急性肾小管损伤。
- 移植肾活检显示近端小管波形蛋白表达较植入活检增加。
- 非HLA抗体筛查检出预存抗波形蛋白抗体。
- 经血浆置换、静脉免疫球蛋白、抗胸腺细胞球蛋白和甲泼尼龙治疗后肾功能恢复。
- 随访1年移植肾功能稳定,估算肾小球滤过率为62mL/min/1.73m2。
关键数值与推荐
- 术前无致敏、抗HLA供者特异性抗体阴性、流式交叉配型阴性。
临床怎么用
- 对传统低免疫风险但发生早期排斥的肾移植受者,可考虑筛查非HLA抗体如抗波形蛋白抗体。
局限性
- 单例病例报告,无法确立因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Improving precision in predicting alloreactivity is an important unmet need and may require individualized consideration of non-HLA antibodies. We report a 21-year-old man with kidney failure from immunoglobulin A nephropathy who met all traditional criteria for a "low-risk" transplant for immune memory. He was unsensitized and received a haplotype-matched living donor kidney transplant from his mother. There were no anti-HLA donor-specific antibodies and flow cross-match was negative. After immediate function, he developed delayed graft function on postoperative day 2. The transplant biopsy specimen was suggestive of antibody-mediated rejection and acute tubular injury with increased vimentin proximal tubular expression compared to the implantation biopsy specimen. He had a history of juvenile idiopathic arthritis, and non-HLA antibody screening demonstrated preformed anti-vimentin antibody. He was successfully treated with plasmapheresis, intravenous immunoglobulin, antithymocyte globulin, and methylprednisolone, with renal recovery. The follow-up biopsy specimen demonstrated decreased vimentin expression with decreased alloinflammation, and graft function remains stable at 1 year posttransplantation (estimated glomerular filtration rate, 62mL/min/1.73m2). We postulate that preformed anti-vimentin autoantibodies bound to vimentin expressed on apoptotic tubular epithelial cells induced by ischemia-reperfusion injury and to constitutively expressed vimentin on peritubular capillaries and podocytes. Our case is suggestive of the involvement of anti-vimentin antibody, for which the pathogenic epitopes may be exposed during ischemia-reperfusion injury.
引用
- Rampersad C, Shaw J, Gibson IW, et al. Early Antibody-Mediated Kidney Transplant Rejection Associated With Anti-Vimentin Antibodies: A Case Report. Am J Kidney Dis. 2019. PMID: 31515140. doi:10.1053/j.ajkd.2019.06.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。